50 patients have benefited from CARMAT’s Aeson® artificial heart since the first implantation in 2013
Aeson® establishes itself as an essential breakthrough innovation in the treatment of advanced biventricular heart failure
41 hospitals in 12 countries are trained in implementation, including 33 for commercial activity
Turnover of €2.8 million in 2023, marked by a clear acceleration in sales in the fourth quarter with 11 establishments out of the 17 completed during the year
Turnover of €14 to €20 million anticipated in 2024
Very short-term launch of a capital increase to extend the financial horizon beyond the end of January 2024 and partially finance the Company’s needs over 12 months, estimated at a minimum of €50 million
CARMAT (FR0010907956, ALCAR, PEA-PME eligible), designer and developer of the most advanced total artificial heart in the world, aiming to offer a therapeutic alternative to patients suffering from advanced biventricular heart failure (the “Company” or “CARMAT”) , announces having reached the milestone of 50 implantations of its total artificial heart and takes stock of its achievements and prospects.
To receive all CARMAT financial information in real time, request it by email to [email protected]. Your registration will be immediate.